COMP <GO>
GKOS vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Glaukos Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GKOS 4
— JNJ 9
■ METRIC PARITY
LAST: $237.60 (-2.01%) • MKT CAP: $14.35B
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GKOS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GKOS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 67.90% | -12.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.70% | 25.50% | -39.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 2.97% | -3.13 | JNJ | /fcf-yield <GO> |
| Operating Margin | -39.30% | 34.70% | -74.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -37.00% | 28.50% | -65.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 32.30% | 6.00% | +26.30 | GKOS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | GKOS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | GKOS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 82.6 | 60.4 | +22.23 | GKOS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.08 | -0.04 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 23.0x | +11.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.35B | $662.49B | -$648.14B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GKOS REV | JNJ REV | GKOS GROSS % | JNJ GROSS % | GKOS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $507.4M | $94.19B | 55.7% | 67.9% | -$22.5M | $19.70B |
| FY 2024 | $383.5M | $88.82B | 75.5% | 69.1% | -$67.6M | $19.84B |
| FY 2023 | $314.7M | $85.16B | 44.0% | 44.0% | -$71.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GKOS // BETA 1.04
JNJ // BETA 1.08